drugset / Trial / NCT03130426
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising iGlarLixi, metformin, and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.
Timeline
- Start
- 2017-06-27
- Primary completion
- 2019-06-30
- Completion
- 2020-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 2000 mg | Oral |
| Subject | iGlarLixi | Unknown | — | Subcutaneous |
| Subject | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |